Daiichi Sankyo Uses Generics Sales To Surpass Astellas As Japan's Top Drug Maker
This article was originally published in PharmAsia News
Executive SummaryDaiichi Sankyo's sales of generics drugs have helped the firm pass Astellas Pharma to become Japan's biggest drug maker in terms of sales
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.